667403-46-5

Usage

Uses

N-(2,5-Dichlorobenzoyl)glycine is an amino acid derivative.

InChI:InChI=1/C9H7Cl2NO3/c10-5-1-2-7(11)6(3-5)9(15)12-4-8(13)14/h1-3H,4H2,(H,12,15)(H,13,14)

Upstream product

• 50-79-3 2,5-dichlorobenzoic acid 
• 56-40-6 glycine 
• 6000-43-7 2-aminoethanoic acid hydrochloride 
• 2905-61-5 2,5-dichlorobenzoyl chloride 

Downstream Products

• 1201903-02-7 2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexa-hydro-2H-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-2-oxoethyl]benzamide 
• 1239908-20-3 2,2’-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid 

Relevant academic research and scientific papers

PROCESS FOR MAKING IXAZOMIB OR INTERMEDIATES THEREFOR

This invention relates to a process for preparing Ixazomib 1, its trimer 1.trimer, its citrate ester 2 or an intermediate for their synthesis. The process comprising at least one amide coupling reaction in the presence of a cyclic alkyl triphosphonic anhy

Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids

Boronic acids are an increasingly important compound class for many applications, including C-C bond formation reactions, medicinal chemistry, and diagnostics. The deprotection of boronic ester intermediates is frequently a problematic and inefficient step in boronic acid syntheses. We describe an approach that highly facilitates this transformation by leveraging the volatility of methylboronic acid and its diol esters. The method is performed under mild conditions, provides high yields, and eliminates cumbersome and problematic purification steps.

p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION

A p53 degradation inducing molecule which can induce degradation of p53 proteins or p53 composites, and a pharmaceutical composition containing said p53 degradation inducing molecule are provided. This p53 degradation inducing molecule is a conjugate of a p53 affinity molecule which has affinity for p53 proteins or p53 composites, and a proteolysis induction tag which has affinity for protease and which does not inhibit proteolysis of proteins by protease.

Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION

A Ras protein degradation inducing molecule that can induce degradation of Ras proteins, and a pharmaceutical composition that contains this Ras protein degradation inducing molecule are provided. The Ras protein degradation inducing molecule is a conjugate of a Ras protein affinity molecule which has affinity to Ras proteins, and a proteolysis-inducing tag which has affinity to protease and does not inhibit proteolysis of proteins by the protease.

Synthetic process research of ixazomib

The invention discloses a synthesis method of ixazomib. The yield and the purity of a target product can be greatly increased with the method.

SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND APPLICATION THEREOF

A substituted boric acid compound, a pharmaceutical composition comprising same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.

Synthesis and application of peptide borate compounds

The invention belongs to the field of drug synthesis, and specifically relates to a series of novel peptide borate compounds or pharmaceutical salts thereof, and a preparation method and pharmaceutical application thereof. The structure of the peptide borate compounds or the pharmaceutical salts thereof is as shown in a formula I which is described in the specification. The compounds of the invention can be used for preparing proteasome inhibitors, and thus can be further used for treating solid tumors and blood tumors.

PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF

Provided are: a protein degradation inducing tag which is a molecule that has affinity with proteases and does not inhibit degradation of a protein by proteases; a protein degradation inducing molecule that is a conjugate of at least one protein degradation inducing tag and at least one protein binding molecule that binds to a protein; and a usage of those.

A PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE

The present invention relates to a process for the preparation of compound of formula (I), wherein, R1 and R2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or R1 and R2 together form a moiety derived from an alpha-hydroxy carboxylic acid compound or a beta-hydroxy carboxylic acid compound, wherein the atom attached to boron in each case is an oxygen atom; or R1 and R2 together form the boronate esters of boronic acid.

Synthesizing method of boric acid citric acid ester compounds including ixazomib

The invention relates to a method for synthesizing ixazomib. The method includes the steps of firstly, using 2,5-dichlorobenzoyl chloride or 2,5-dichlorobenzoic acid as the initial raw material, subjecting the 2,5-dichlorobenzoyl chloride or 2,5-dichlorobenzoic acid and glycine ester to condensation reaction to prepare N-(2,5-dichlorobenzoyl) glycine ester, and performing de-protection reaction toobtain N-(2,5-dichlorobenzoyl) glycine; secondly, subjecting the N-(2,5-dichlorobenzoyl) glycine obtained in the first step and (R)-leucine boric acid pinacol ester to condensation reaction to prepare (R)-[N-(2,5-dichlorobenzoyl) glycyl] leucine boric acid pinacol ester; thirdly, allowing the(R)-[N-(2,5-dichlorobenzoyl) glycyl] leucine boric acid pinacol ester obtained in the second step to haveone-step reaction with citric acid to generate the ixazomib. The invention further relates to a method for synthesizing boric acid citric acid ester compounds, and the method includes allowing boric acid pinacol ester to have one-step reaction with citric acid to generate the boric acid citric acid ester compounds. By the methods, the boric acid citric acid ester compounds including the ixazomib can be conveniently synthesized.